Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 26atezolizumab 14Nivolumab 13Gemcitabine 13Cisplatin 10Docetaxel 8Carboplatin 8avelumab 7Mitomycin 7epacadostat 4cabozantinib 4Ipilimumab 4pemigatinib 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Bevacizumab 3vofatamab 2rucaparib 2lenvatinib 2enfortumab vedotin 2durvalumab 2cabazitaxel 2bempegaldesleukin 2Standard of Care 2Rogaratinib 2Ramucirumab 2Radiation 2Platinum 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Transitional Cell × apatorsen × Clear all
NCT01780545 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Hoosier Cancer Research Network

Phase 2 Completed
200 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡